- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.09. | Arecor Therapeutics: Directorate Changes | - | RNS | ||
| 25.09. | AIM Market Roundup: Wishbone, Nativo Resources, Arecor Therapeutics | 1 | The Armchair Trader | ||
| 25.09. | Arecor Therapeutics extends cash runway with US partnerships | 2 | The Armchair Trader | ||
| 25.09. | Arecor Therapeutics PLC: Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292 | 75 | GlobeNewswire (Europe) | This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc("Arecor" or the "Company")... ► Artikel lesen | |
| 25.09. | Arecor Therapeutics - Interim results for the six months to 30 June 2025 | - | RNS | ||
| 25.09. | Arecor Therapeutics - Co-Development Agreement & Monetisation Deal | - | RNS | ||
| ARECOR THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.09. | Arecor Therapeutics - Notice of Interim Results | - | RNS | ||
| 04.09. | Arecor Therapeutics - Positive FDA Feedback on Phase 2 Study Design | 2 | RNS | ||
| 08.08. | Arecor Therapeutics - Change of Auditor | 1 | RNS | ||
| 14.07. | Arecor gründet wissenschaftlichen Beirat für orale Peptid-Verabreichung | 1 | Investing.com Deutsch | ||
| 14.07. | Arecor forms scientific advisory board for oral peptide delivery | 1 | Investing.com | ||
| 14.07. | Arecor Therapeutics - Arecor Establishes New Scientific Advisory Board | - | RNS | ||
| 04.06. | Arecor Therapeutics - Grant of Options and PDMR Dealing | - | RNS | ||
| 02.06. | Arecor Therapeutics - Result of AGM | - | RNS | ||
| 02.06. | Arecor Therapeutics - Non-Executive Director Board Change | - | RNS | ||
| 21.05. | Arecor Therapeutics - Director/PDMR Dealing | 1 | RNS | ||
| 20.05. | Skye and Arecor to develop higher formulation of CB1 inhibitor | 2 | Pharmaceutical Technology | ||
| 19.05. | AIM Market Roundup: The Revel Collective, Tanfield, Arecor | 3 | The Armchair Trader | ||
| 19.05. | Arecor enters formulation partnership with Skye Bioscience | 2 | Sharecast | ||
| 19.05. | Skye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab | 362 | GlobeNewswire (Europe) | SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 48,960 | -1,57 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,550 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| NUVALENT | 89,75 | +1,79 % | Nuvalent präsentiert neue Daten zu HER2-Inhibitor auf Krebskonferenz | ||
| TARSUS PHARMACEUTICALS | 70,34 | +0,31 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| ARCELLX | 86,23 | -0,65 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| QIAGEN | 40,955 | +1,20 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,720 | +3,34 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,390 | 0,00 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| COGENT BIOSCIENCES | 16,200 | -0,31 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| CG ONCOLOGY | 42,960 | -0,72 % | Why Cg Oncology Stock Rocketed 7% Higher Today | ||
| LENZ THERAPEUTICS | 38,610 | -0,34 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| MINERALYS THERAPEUTICS | 43,050 | +9,29 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| 89BIO | 14,800 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,030 | -0,04 % | Dyne cut to Perform at Oppenheimer on valuation | ||
| TREVI THERAPEUTICS | 9,710 | -2,85 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen |
ARECOR THERAPEUTICS PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,035 (-5,65 %) liegt der Kurs bei 0,585 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARECOR THERAPEUTICS PLC finden Sie auf Wallstreet Online.